International Brain Tumour Awareness Week - 20-27th October 2018. More info click here.

IBTA e-News February 2018 released

By 3rd March 2018News archive
[28 February 2018] The IBTA's monthly e-News has now been released and has been emailed to all subscribers. To sign up to receive your copy, click here.

You can read the IBTA e-News February 2018 edition in full online here.

Some of the highlights from this month's include:

  • Further analysis of a phase 3 clinical trial of 'Tumor-Treating Fields' via Novocure's 'Optune' portable medical device does not negatively impact health-related quality of life and resulted in significantly longer deterioration-free survival in glioblastoma patients.
  • Experiments have shown that the sickle cell disease drug hydroxyurea may increase the effectiveness of temozolomide chemotherapy in glioblastoma.
  • Cancer survival across the globe is increasing, but adult brain tumour survival is “generally rather flat”, according to research published in the journal The Lancet. The report concluded that childhood brain tumours tend to have a better overall outcome than adult brain tumours
  • A Danish nationwide study published in BMJ Open has found that children who have been hospitalised with pneumonia have increased rates of brain tumours, among other cancers. Reasons for this observation are currently unclear.
  • A European research collaboration of biologists and electronic engineers are to develop microtechnology ‘lab-on-chip’ devices designed to identify glioblastoma and medulloblastoma cells rapidly.
  • Results from a phase 2 clinical trial of bevacizumab (Avastin) in paediatric patients with high-grade glioma show that the drug does not improve event-free survival when it is added to standard care.
  • A phase 3 clinical trial of VAL-083, a “first-in-class” chemotherapy agent, has now opened for glioblastoma patients whose disease has progressed during or after standard treatment with chemo-radiation
  • The first patient with newly-diagnosed inoperable glioblastoma has been dosed in a phase 3 clinical trial of trans sodium crocetinate (TSC). A previous phase 2 trial showed nearly a four-fold increase in survival with TSC, compared with historical data.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.